What is the Iranian Pharmaceutical Industry?
Iran’s pharmaceutical industry is in the midst of an unprecedented period of growth and innovation, as the country’s pharmaceutical sector continues to benefit from the economic and political reforms that have made Iran a global hub for pharmaceutical production and distribution.
However, while pharmaceuticals have long been a source of great prestige in Iran, this period of rapid growth is set to see a significant increase in the number of pharmaceuticals being sold and sold as a result of the government’s ongoing reform efforts.
The Pharmaceutical Industry Association of Iran (PIAI), which represents Iran’s leading pharmaceutical companies, estimates that Iran’s total pharmaceutical exports to the world reached more than US$7 billion in 2015.
This represents a 60 percent increase in exports over the same period last year, and a 20 percent increase over the previous year.
The growth in Iran’s market share of the pharmaceutical market is largely due to the recent introduction of a new product from the Iranian pharmaceutical industry that is known as the ‘ANI pharmaceuticals’.
This product is produced from a special strain of cannabis, known as kirman, that has been developed and patented in Iran.
Kirman is a potent drug for treating nausea and vomiting, but it also produces a highly-effective painkiller called a tardigrade.
According to PIAI, the average price of kirmen was nearly $100 per kilogram in 2015, and the price per kilo is expected to rise to around $150 in 2020.
As of March 2018, the price of tardigade, the drug derived from this strain of karman, was about $130 per kilos.
The rapid growth of Iran’s new drug is a result, in part, of the reforms introduced by the Rouhani administration.
Under Rouhani, Iran’s drug industry has received a significant boost in terms of access to international markets.
The new regime also established a new pharmaceutical licensing authority, which will allow for the production of new pharmaceuticals to be marketed and distributed outside of Iran.
The new legislation was passed in the past year, when the previous licensing authority was dissolved.
Since then, however, there have been several attempts by the government to re-establish the authority.
The government is also trying to strengthen its control over the production and marketing of pharmaceutical products, by strengthening licensing authorities and restricting the export of products from other countries.
The reform of the Iranian pharma industry has not only benefited the country, but also the pharmaceutical industry in general.PIAIF is one of the largest pharmaceutical organizations in the world, representing the countrys leading pharmaceutical manufacturers and exporters.
It has over 4,000 members and works with over 200 companies in all stages of production and sale of pharmaceutical drugs.
The organization works in partnership with companies that have a significant presence in the pharmaceutical sector, such as Medivation, which has over 20,000 employees and has been awarded a license by the U.S. Food and Drug Administration to manufacture medical devices and other products from its plants.
In 2015, PIAIF helped create a system for monitoring the pharmaceuticals industry, which currently comprises a team of representatives from the FDA, the U and UK, the European Medicines Agency (EMA) and the International Pharmaceutical Federation (IPF).
PIAIAI also supports the development of new technologies that can be used to reduce drug side effects and improve the quality of pharmaceutical medicines, such the use of bio-technology to create drug-based solutions.
For the past two years, PHAI has been actively involved in the ongoing development of the Iran BioTech project, which is currently being implemented in conjunction with Medivation.
In this project, pharmaceutical companies are collaborating with international partners to develop innovative medicines that are derived from plant and animal tissue, such those created from human embryos and the bioengineered embryos of animals.
According for the bio-engineered embryo, the plant is a source for a new therapeutic compound called nonylphenol.
This new compound, which PIA IAI has created to treat nausea and pain, is a component of the new medicine, which the FDA has approved for use in Iran and other countries in the Middle East.
The FDA approved the drug in January 2018, and by the end of 2019, Pia IAI expects to receive the final license from the US Food and Drugs Administration.
As of March, PIANI estimates that the new drug will be in clinical trials in the United States, China, South Korea, France, Russia, Japan, India, Austria, Switzerland and other European countries.
The PIAHI project was approved by the FDA in January 2020, and will be implemented in the U, United Kingdom and other nations in the coming months.
It will be the first time that a pharmaceutical product has been approved by both the FDA and the FDA.
It is expected that the UPRI and IAI will collaborate on a comprehensive review of the technology before it is used in clinical trial, which would take place after a